October 2019 Vol 10, No 10
Our role as oncology nurse and patient navigators is to remove barriers to care for our patients.
Shelly Cummings, MS, CGC1, Lavinia Dobrea, RN, MS, OCN, Joann N. Bodurtha, MD, MPH, FAAP, FACMG, Frank dela Rama, RN, MS, AOCNS, AGN-BC, Danelle Johnston, MSN, RN, OCN, HON-ONN-CG, Leigha Senter-Jamieson, MS, LGC, Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG, Jennifer R. Klemp, PhD, MPH, MA
Incorporating genetics and genomics in oncology nursing care is key to advancing treatment modalities and care for current and future patients.
Madelaine Binner, DNP, MSN, MBA, CRNP-BC, Alyson Figlioli, BS, RN, CBCN, Jacqueline Shanahan, BSN, RN, OCN, Judeth Davis, BSN, RN, OCN, Teresa Putscher, BSN, BA, RN, OCN, Kimberly Stewart, BSN, RN, CBCN, Kip Waite, BA
The authors present an initiative that aims to develop metrics and analyze the role of oncology nurse navigators in value-based care.
Danelle Johnston, MSN, RN, OCN, HON-ONN-CG, Tricia Strusowski, RN, MS, Nicole Messier, RN, BSN, ONN-CG, OCN, Lianna Willhite, RN, BSN, ONN-CG, CBCN
This highly anticipated navigation acuity tool will aid navigators in identifying levels of patient acuity based on the barriers to care, weights of the barriers, and level of patient distress.
Moving combination immunotherapy into the neoadjuvant setting for patients with stage III melanoma induces a higher rate of pathologic response than adjuvant therapy, said Christian U. Blank, MD, PhD, Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium.
Unlike side effects associated with common cancer treatments like chemotherapy and radiation, side effects from immunotherapy can arise months or even years after treatment is completed and can affect any organ system.
Fixed-Duration Targeted Therapy with Venetoclax plus Obinutuzumab New Frontline Standard for Patients with Chronic Lymphocytic Leukemia
In the phase 3 CLL14 trial, fixed-duration therapy with the combination of venetoclax plus obinutuzumab was superior to the combination of chemotherapy with chlorambucil plus obinutuzumab as frontline therapy in older patients with chronic lymphocytic leukemia (CLL) and comorbidities.
Gilteritinib, a recently approved FLT3 inhibitor, prolonged survival in patients with relapsed or refractory acute myeloid leukemia (AML) and an FLT3 mutation in the phase 3 ADMIRAL clinical trial.
Results 1 - 9 of 9